EUVIMEDEUVIMED entdecken
Crossref

Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation

Shikhar Mohan, Yi Li, Kevin Chu, Liliana De La Paz, Diana Sperger, Bing Shi, Chris Foti, Victor Rucker, Chiajen Lai iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Shikhar Mohan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California 94404, United States. Hauptthemen laut MEDLINE: Solubility, Fumarates, Drug Compounding, Chemistry, Pharmaceutical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report a novel utilization of a pH modifier as a disproportionation retardant in a tablet formulation. The drug molecule of interest has significant bioavailability challenges that require solubility enhancement. In addition to limited salt/cocrystal options, disproportionation of the potential salt(s) was identified as a substantial risk. Using a combination of Raman spectroscopy with chemometrics and quantitative X-ray diffraction in specially designed stress testing, we investigated the disproportionation phenomena. The learnings and insight drawn from crystallography drove the selection of the maleate form as the target API. Inspired by the fumarate form's unique stability and solubility characteristics, we used fumaric acid as the microenvironmental pH modulator. Proof-of-concept experiments with high-risk (HCl) and moderate-risk (maleate) scenarios confirmed the synergistic advantage of fumaric acid, which interacts with the freebase released by disproportionation to form a more soluble species. The resultant hemifumarate helps maintain the solubility at an elevated level. This work demonstrates an innovative technique to mediate the solubility drop during the "parachute" phase of drug absorption using compendial excipients, and this approach can potentially serve as an effective risk-mitigating strategy for salt disproportionation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SolubilityFumaratesDrug CompoundingChemistry, PharmaceuticalHydrogen-Ion ConcentrationSpectrum Analysis, RamanX-Ray DiffractionTabletsSaltsMaleatesExcipientsBiological Availability

Stichwörter der Autor:innen

Raman spectroscopyX-ray diffractionchemometricsformulationmicroenvironmental pHpH modifiersalt disproportionationspring-and-parachute

Substanzen

Fumaratesfumaric acidTabletsSaltsMaleatesExcipients

Autor:innen und Institutionen

  • Gilead Sciences, Inc., Foster City, California 94404, United States.
  • Velexi Corporation, Burlingame, California 94010, United States.

ORCID-Profile: Chiajen Lai

Zitieren

APA

Mohan, S., Li, Y., Chu, K., De La Paz, L., Sperger, D., Shi, B., Foti, C., Rucker, V., & Lai, C. (2024). Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00166

Vancouver

Mohan S, Li Y, Chu K, De La Paz L, Sperger D, Shi B, et al. Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00166

BibTeX
@article{Mohan2024,
  author = {Mohan, Shikhar and Li, Yi and Chu, Kevin and De La Paz, Liliana and Sperger, Diana and Shi, Bing and Foti, Chris and Rucker, Victor and Lai, Chiajen},
  title = {Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00166}
}
Kostenlos starten →